1 October we become SureStone CapitalSame team, same ABN. Our website and email addresses move to surestone.com.au.
Preparing video
Key points:
Market volatility driven by quantitative fund flows and portfolio shiftsBiotech and healthcare seen as undervalued sectors with recovery potentialClarity Pharmaceuticals (ASX:CU6) highlighted for significant developments in diagnosticsUS tech and AI chip leaders Nvidia (NASDAQ: NVDA) and Taiwan Semiconductor (NYSE: TSM) remain central to growth strategies
Michael Frazis of Frazis Capital Partners shares that recent market movements reflect significant volatility, including a rally into February followed by a major sell-off, largely driven by quantitative funds. Frazis states that July saw the bulk of buying pressure returning, resulting in a strong rebound. He points to nimble, quantitative approaches as vital for navigating these rapid market dynamics and capturing upside amid large fund flows.
Turning to sector rotation, Frazis finds US tech, particularly small-cap growth and names such as Credo (NASDAQ: CRDO) and Elf Cosmetics (NYSE: ELF), as the market’s “red hot” segment, though he views this as increasingly risky after sharp gains. He highlights healthcare and biotech as undervalued globally and in Australia, with renewed investor interest following several difficult years. Frazis singles out Clarity Pharmaceuticals (ASX:CU6), noting its rapid $200 million capital raise, significant short interest, and potential due to progress in gene therapy diagnostics. He suggests a positive head-to-head trial could drive major market share gains for Clarity.
Frazis observes that large-caps like CSL (ASX:CSL) and ResMed (ASX:RMD) have been out of favour but show potential as the sector turns a corner. He identifies Nvidia and Taiwan Semiconductor as critical beneficiaries of AI demand, while outlining plans to launch a global growth-focused ETF to capture opportunities beyond the ASX.
